Trial Profile
Phase III pivotal trial of a long-acting intramuscular injection of glatiramer acetate (GA Depot) in patients with relapsing remitting multiple sclerosis (RRMS)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2019
Price :
$35
*
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Mapi Pharma
- 18 Mar 2019 According to a Mapi Pharma media release, this trial is expected to begin in 2019.
- 05 Nov 2018 According to a Mapi Pharma media release, Mapi Pharma has completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co. funds raised will support Mapis future development and enable the expansion of the companys pipeline to additional 505(b)(2) and this trial.
- 31 Oct 2017 According to a Mapi Pharma media release, this trial is expected to initiate in 2018.